**Core Concept**
Sulfonylureas are a class of medications used to treat type 2 diabetes mellitus, specifically to stimulate insulin release from pancreatic beta cells. The primary mechanism of action involves the closure of potassium (K+) channels in these cells, leading to an increase in insulin secretion.

**Why the Correct Answer is Right**
The correct mechanism of action of sulfonylureas involves the binding of these drugs to the sulfonylurea receptor (SUR1) on the pancreatic beta cell membrane. This receptor is closely associated with a potassium (K+) channel, which is part of the ATP-sensitive potassium channel complex (K_ATP channel). The binding of sulfonylureas to SUR1 causes a conformational change, leading to the closure of the K+ channel. This closure results in an increase in cellular ATP levels, which activates the ATP-sensitive potassium channel and triggers the closure of the voltage-dependent calcium channels. The subsequent increase in intracellular calcium concentration ([Ca2+]i) triggers the exocytosis of insulin-containing secretory granules, resulting in insulin release.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it is a repetition of the correct answer and does not provide any additional information.

**Option B:** This option is incorrect because sulfonylureas do not primarily act through the blockade of sodium (Na+) channels. Sodium channels are involved in the regulation of cardiac and neuronal excitability, rather than insulin secretion.

**Option C:** This option is incorrect because sulfonylureas do not primarily act through the blockade of chloride (Cl-) channels. Chloride channels are involved in various cellular processes, including osmoregulation and neurotransmission, but are not directly involved in insulin secretion.

**Option D:** This option is incorrect because sulfonylureas do not primarily act through the blockade of calcium (Ca2+) channels. While calcium channels are involved in insulin secretion, sulfonylureas primarily act through the blockade of potassium channels, which indirectly leads to the closure of calcium channels.

**Clinical Pearl / High-Yield Fact**
A key aspect of sulfonylurea therapy is the risk of hypoglycemia due to the increased insulin secretion. Patients taking sulfonylureas should be advised to monitor their blood glucose levels regularly and to adjust their diet and medication regimen accordingly.

✓ Correct Answer: A. K+ ATP channel blocker.